Fulgent Genetics, Inc. (FLGT)

Over the past six months, Fulgent Genetics' stock has shown a 14.06% increase. Fulgent Genetics reported its Q3 2025 earnings, posting an EPS of $0.14, significantly exceeding analysts' expectations of -$0.36 by 138.89%, and revenue of $84.07 million, surpassing analyst estimates of $81.43 million. Fulgent Genetics announced an agreement to acquire Bako Diagnostics and StrataDx. Fulgent Genetics' shares jumped 13.5% in premarket trading following the release of its Q2 2025 investor presentation, reporting quarterly core revenue of $82 million, a 16% year-over-year increase, and beat earnings expectations with an EPS of $0.04 compared to a forecasted -$0.08. Analysts have reissued and adjusted ratings and price targets for FLGT, with Raymond James reissuing a "Buy" rating and bumping its price target to $25, while Piper Sandler maintained a "Hold" rating but raised its price target from $16 to $23 a share. Raymond James Financial restated an "outperform" rating and issued a $36.00 target price, and Piper Sandler lifted their target price from $21.00 to $30.00 and gave the stock a "neutral" rating.

Fulgent Genetics' products and services can experience demand seasonality, particularly in its laboratory services business. The company has noted that the latter half of the year may see a slowdown due to elective surgeries and biopsies being postponed past the holiday season. However, the company also expressed optimism that progress in new wins and pipeline strength might help to mitigate some of this seasonality.

Fulgent Genetics, Inc. is a technology company specializing in genetic testing and diagnostic services, providing clinically actionable diagnostic information to physicians, operating within the Healthcare sector, primarily in the Diagnostics & Research and Healthcare Providers and Services industries. The company's business is divided into laboratory services and therapeutic development. The laboratory services segment generates the majority of its revenue, including technical laboratory services and professional interpretation of results by licensed physicians. Its therapeutic development business focuses on creating drug candidates for various cancers. The company's comprehensive product portfolio encompasses a wide range of genetic testing and sequencing solutions, including genes and panels, known mutation testing, hereditary cancer panels, carrier screening, tumor profiling solutions, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays, such as COVID-19 diagnostics. Fulgent also offers anatomic pathology laboratory tests and services. The company provides both clinician-ordered and direct-to-consumer testing models, as well as custom research services for biopharmaceutical partners and academic institutions. Its proprietary platform, Picture Genetics, integrates gene probes, data suppression and comparison algorithms, adaptive learning software, and laboratory information management systems to help customers identify health markers in their personal DNA.

Fulgent Genetics, Inc. primarily generates the vast majority of its revenue from the United States, with additional operations in select international markets.

In the past year, Fulgent Genetics has maintained a generally positive brand reputation among analysts, with a consensus rating of "Moderate Buy" based on reports from five analysts. The average 12-month target price among brokerages is $32.00, representing a potential upside from its current price. MarketBeat's MarketRank™ scored Fulgent Genetics higher than 68% of evaluated companies. The company's ability to exceed earnings expectations, such as in Q2 and Q3 2025, likely contributed positively to its reputation. The acquisition of Bako Diagnostics and StrataDx could enhance the company's market position and reputation by expanding its diagnostic offerings. Several analysts have reiterated or upgraded their ratings and increased price targets, reflecting a positive outlook on the company's future performance, with Zacks Research upgrading Fulgent Genetics from a "hold" to a "strong-buy" rating on January 9, 2026.

Institutional investors hold over 50% of Fulgent Genetics, Inc., indicating their significant influence on board decisions. As of January 27, 2026, 318 institutional owners and shareholders have filed 13D/G or 13F forms, holding a total of 19,708,534 shares. Major institutional shareholders include BlackRock, Inc., Millennium Management LLC, Vanguard Group Inc, Acadian Asset Management LLC, Dimensional Fund Advisors LP, Northwestern Mutual Wealth Management Co., D. E. Shaw & Co., Inc., and State Street Corp. The company's CEO, Ming Hsieh, is the largest individual shareholder, holding 28% of outstanding shares. Other insiders who own company stock include Hanlin Gao, Paul Kim, and Jian Xie. Individual investors, generally the public, hold a 10% stake in Fulgent Genetics.